Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

How Trends in Life Science Consultancy Influence Industry Events

Aug 02, 2025

Understanding Life Science Consultancy Trends

In recent years, the life science consultancy sector has experienced significant changes, driven by evolving technologies and regulatory landscapes. These trends are not only affecting how consultancies operate but also influencing the nature and focus of industry events. Understanding these trends is crucial for stakeholders looking to stay ahead in this dynamic environment.

One major trend is the increasing emphasis on data analytics and digital transformation. Life science companies are leveraging big data to gain insights into product development, regulatory compliance, and market strategies. This shift is reflected in industry events, where data-driven decision-making often takes center stage.

life science data

The Rise of Personalized Medicine

Another significant trend is the growing focus on personalized medicine. As technology advances, the ability to tailor medical treatments to individual patients becomes more feasible. Life science consultancies are now providing expertise in genomics and personalized healthcare solutions, influencing content at industry conferences and seminars.

Events are increasingly featuring discussions and workshops on the integration of personalized medicine into traditional healthcare models. This trend highlights the need for stakeholders to adapt quickly to new scientific discoveries and methodologies.

Regulatory Changes and Compliance

Regulatory landscapes are continuously evolving, posing both challenges and opportunities for life science consultancies. New regulations often require consultancies to provide updated guidance and compliance strategies. Consequently, industry events have become platforms for discussing regulatory changes and best practices in compliance.

regulatory compliance

Such events often feature panels with regulatory experts who offer insights into navigating complex legal frameworks. This aspect is particularly crucial for companies operating in multiple countries, where understanding diverse regulatory requirements is vital.

Innovation in Biotechnology

Biotechnology continues to be a driving force in the life sciences sector, with innovations such as CRISPR and other gene-editing technologies gaining prominence. Life science consultancies are at the forefront of integrating these innovations into practical applications, influencing the themes of industry events.

Conferences now frequently explore topics like ethical considerations in biotechnology and the potential societal impacts of new technologies. Attendees are eager to learn about the latest breakthroughs and their implications for future healthcare solutions.

biotechnology innovation

Networking and Collaboration Opportunities

Industry events serve as a crucial networking platform where professionals can connect, share knowledge, and collaborate on projects. The emphasis on collaboration has grown with the realization that interdisciplinary approaches often yield the best results in life sciences.

Many events now include sessions specifically designed for fostering partnerships between academia, industry leaders, and regulatory bodies. These collaborative efforts are essential for driving innovation and addressing complex challenges in the sector.

Conclusion

The trends in life science consultancy are undoubtedly shaping the landscape of industry events. From data analytics to personalized medicine, these emerging themes are influencing the topics discussed and the types of interactions that occur at these gatherings. Staying informed about these trends is essential for anyone involved in life sciences, ensuring they remain competitive and forward-thinking in an ever-evolving industry.